<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00152490</url>
  </required_header>
  <id_info>
    <org_study_id>C87031</org_study_id>
    <nct_id>NCT00152490</nct_id>
  </id_info>
  <brief_title>A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)</brief_title>
  <official_title>A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Safety and Efficacy of the Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed at Weeks 0, 2, 4 Then 4-weekly to Week 24), in the Treatment of Patients With Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <brief_summary>
    <textblock>
      A 26 week study to examine the efficacy, safety and pharmacokinetics of CDP870 in Crohn's
      disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Receiving immunosuppressants (azathioprine/6-MP/methotrexate) at Week 0 or not.

      604 patients will be enrolled with 1006 patients screened (to allow for 25% screen failures
      between screening and Week 0 and expected presentation at Screening of 60% of patients with
      CRP &lt; 10 mg/L and 40% of patients with CRP ≥ 10 mg/L).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In the population with CRP ≥ 10 mg/L at baseline</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical response at week 6</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical response at week 6 and week 26</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>In the population with CRP ≥ 10 mg/L at baseline - % patients in clinical remission at Week 6; % patients in clinical remission at both Week 6 and Week 26; % patients with IBDQ response at Week 6; % patients with IBDQ response at both Week 6 and Week 2</measure>
  </secondary_outcome>
  <enrollment>604</enrollment>
  <condition>Crohn's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certolizumab Pegol (CDP870)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Definitive diagnosis of Crohn's disease confirmed (at least 3 months prior to study
             entry) either by radiological, endoscopic or histological evidence, affecting the
             terminal ileum (L1), colon (L2) or ileocolon (L3*. *Vienna Classification (1998)

          -  Active Crohn's disease (≥ 220 and ≤ 450) scored over the 7 days prior to the first
             dose of study drug.

          -  Male and female aged 18 years or above at screening.

          -  Patients who meet all concomitant medication criteria in the protocol specified table.
             For all drugs being taken at screening, the patient should be able to remain on a
             stable dose throughout the duration of the study, although steroids may be tapered
             starting at Weeks 8 to 12.

        Exclusion Criteria:

          -  Crohn's Disease Related

          -  Fistula abscess present at screening.

          -  Stricturing type disease with symptoms or signs of non-inflammatory mechanical
             obstruction or bowel perforation in last 3 months.

          -  Short bowel syndrome.

          -  Functional colostomy or ileostomy (note: patients who have had a temporary stoma in
             the past, which has been reversed, are eligible to enter the study).

          -  Positive stool laboratory results for enteric pathogens.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/C87031_CSS_20080608.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <results_reference>
    <citation>Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S; PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007 Jul 19;357(3):228-38.</citation>
    <PMID>17634458</PMID>
  </results_reference>
  <results_reference>
    <citation>Rutgeerts P, Schreiber S, Feagan B, Keininger DL, O'Neil L, Fedorak RN; CDP870 Crohn's Disease Study Group. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis. 2008 Mar;23(3):289-96. Epub 2007 Dec 11.</citation>
    <PMID>18071721</PMID>
  </results_reference>
  <results_reference>
    <citation>Reilly MC, Gerlier L, Brabant Y, Brown M. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther. 2008 Feb;30(2):393-404. doi: 10.1016/j.clinthera.2008.02.016.</citation>
    <PMID>18343277</PMID>
  </results_reference>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>September 6, 2013</last_update_submitted>
  <last_update_submitted_qc>September 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <keyword>Crohn's disease, CDP870, CDAI, clinical response, remission,</keyword>
  <keyword>Certolizumab Pegol, Cimzia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

